Radiotherapy & Oncology
Volume 93, Issue 3 , Pages 414-418, December 2009

Low rate of thoracic toxicity in palliative paraspinal single-fraction stereotactic body radiation therapy

Department of Radiation Oncology, Memorial Sloan-Kettering Cancer Center, New York, NY, USA

Received 9 June 2009; received in revised form 29 September 2009; accepted 11 October 2009. published online 18 November 2009.

Abstract 

Background

There has been an increase in the utilization of single-fraction stereotactic body radiation therapy (SBRT) to treat thoracic structures, but there have been few reports describing toxicity outcomes with this treatment.

Methods

We evaluated 119 sites (114 patients) with no prior history of thoracic radiation were treated from 10/1/2003 to 10/27/2008 with single-fraction SBRT to thoracic structures. The median dose to the gross tumor volume was 2400cGy (range 1800–2400cGy), as was the median dose to the planning target volume (range 1600–2400cGy). A detailed review of thoracic toxicities was performed to include pneumonitis or Grade 2 or higher esophageal and bronchial toxicity. In addition, we retrospectively contoured the esophagus and bronchus of 48 patients treated in 2004–2005, prior to the establishment of dose constraints to determine the range of doses that these structures received.

Results

Of the contoured patients, the median dose to the hottest 1cc (D1cc) of the esophagus was 1250cGy (range 158–2572cGy). The median bronchial D1cc was 1101cGy (range 260–2211cGy). At a median follow-up of 11.6months, there were seven Grade 2 or higher esophageal toxicities, including one Grade 3 and one Grade 4 toxicities. There were two bronchial toxicities, one Grade 2 and one Grade 3. There were no cases of pneumonitis.

Conclusions

High-dose single-fraction SBRT is well tolerated to the thoracic region, with most patients tolerating high doses to central structures without significant toxicity.

Keywords: Stereotactic body radiation therapy, Esophagus, Bronchus, Hypofractionation

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S0167-8140(09)00611-2

doi:10.1016/j.radonc.2009.10.017

Radiotherapy & Oncology
Volume 93, Issue 3 , Pages 414-418, December 2009